Last updated: September 24, 2026
Anti-inhibitor coagulant complex, marketed primarily as FEIBA [Anti-Inhibitor Coagulant Complex (Bovine)], is a plasma-derived bypassing agent for patients with hemophilia A or B who have inhibitors against factor VIII or factor IX. Takeda is the principal global commercial sponsor following its acquisition of Shire, which acquired Baxalta from Baxter. The product remains commercially relevant for acute bleeding and surgery, but its long-term growth is constrained by prophylactic non-factor therapies, especially emicizumab.
Public filings do not disclose a complete standalone global revenue series for FEIBA. Takeda reports the product within broader plasma-derived and hematology categories, limiting precise market-share and product-level valuation analysis. The financial trajectory is best characterized as mature and defensive rather than growth-oriented.
What is anti-inhibitor coagulant complex and how is it used?
FEIBA is a human plasma-derived concentrate containing activated and nonactivated clotting factors. Its activity bypasses the inhibited factor VIII or factor IX pathway and promotes thrombin generation.
| Attribute |
Details |
| Generic name |
Anti-inhibitor coagulant complex |
| Principal brand |
FEIBA |
| Product type |
Plasma-derived coagulation-factor complex |
| Primary use |
Treatment and prevention of bleeding in hemophilia A or B with inhibitors |
| Sponsor |
Takeda Pharmaceuticals |
| Regulatory category |
Biologic, plasma-derived coagulation product |
| Administration |
Intravenous infusion |
| Main alternatives |
Emicizumab, recombinant activated factor VII, porcine factor VIII, immune tolerance induction |
| Principal risks |
Thrombosis, disseminated intravascular coagulation, hypersensitivity and infusion reactions |
The product is used for breakthrough bleeds, perioperative management and other situations in which conventional factor replacement is ineffective. Its role is different from emicizumab, which is primarily a prophylactic therapy rather than an on-demand bypassing agent.
The FDA label warns against combining FEIBA with emicizumab because of the risk of thrombotic microangiopathy and thrombotic events, particularly when high cumulative doses of FEIBA are administered (FDA, 2020).
What is the FDA regulatory status of FEIBA?
FEIBA is an FDA-approved biologic and is regulated under a biologics license application rather than a conventional small-molecule new drug application. The FDA labeling identifies FEIBA as a treatment for bleeding episodes and perioperative management in patients with hemophilia A or B with inhibitors.
The product’s commercial position is supported by clinical familiarity, established manufacturing infrastructure and inclusion in treatment protocols for inhibitor patients. Its regulatory position is mature. The major FDA-related risk is not loss of approval but utilization displacement as physicians adopt newer prophylactic therapies.
The United States has also approved newer treatments that reduce reliance on bypassing agents:
- Emicizumab, marketed as Hemlibra by Roche, provides prophylaxis for hemophilia A with or without factor VIII inhibitors.
- Concizumab, marketed as Alhemo by Novo Nordisk, was approved in the United States in 2024 for routine prophylaxis in hemophilia A or B with inhibitors.
- Marstacimab, marketed as Hympavzi by Pfizer, was approved in the United States in 2024 for routine prophylaxis in hemophilia A or B without inhibitors.
These products expand the competitive pressure on acute bypassing-agent demand, although they do not eliminate the need for rescue therapy.
What patents protect anti-inhibitor coagulant complex?
The principal intellectual-property protection for FEIBA is unlikely to be a currently enforceable composition-of-matter patent. FEIBA was introduced decades ago, and any original product or formulation patents would generally have expired by 2026.
| IP category |
Current commercial relevance |
| Original composition patents |
Likely expired |
| Early formulation patents |
Likely expired |
| Method-of-use patents |
Potentially expired or narrow |
| Manufacturing know-how |
Material and difficult to replicate |
| Plasma-sourcing systems |
Material operational barrier |
| Regulatory exclusivity |
No meaningful remaining new-product exclusivity expected |
| Orange Book listing |
Not a standard protection route for this biologic |
FEIBA is a biologic plasma product, not a conventional small-molecule medicine listed through the standard Orange Book patent-certification framework. The key commercial barriers are manufacturing quality, donor-plasma access, viral inactivation, process validation, clinical comparability and regulatory approval.
Does FEIBA have Orange Book patents?
FEIBA is not principally protected through Orange Book-listed patents. The Orange Book is designed mainly for approved small-molecule drug products and associated patent certifications. FEIBA’s relevant regulatory record is associated with its biologics license and FDA biologics databases.
A generic Paragraph IV challenge is therefore not the normal entry pathway for FEIBA. A competing manufacturer would more likely pursue a biologics license or an appropriate biologic comparability pathway, depending on the FDA’s regulatory classification and reference-product status.
When does anti-inhibitor coagulant complex lose exclusivity?
FEIBA’s effective market exclusivity has already expired in the conventional patent sense. The product’s continued protection comes from cumulative execution barriers:
- Access to qualified human plasma.
- Fractionation and purification capabilities.
- Viral clearance and pathogen-safety controls.
- Batch consistency and potency testing.
- Global pharmacovigilance and supply infrastructure.
- Physician familiarity with dosing and surgical use.
Unlike a newly approved monoclonal antibody, FEIBA does not have a meaningful future patent cliff that would create a discrete generic-entry event. Competition is more likely to appear through alternative bypassing agents, biosimilar-like plasma-derived products or improved non-factor prophylaxis.
How many patents cover FEIBA?
A reliable public count of active patents specifically covering FEIBA cannot be established from standard FDA product databases or Takeda’s public financial reporting. The historical patent estate may include process, formulation, purification and manufacturing claims, but the commercial significance of those claims is not equivalent to a live composition patent.
The absence of a clearly identifiable active composition patent changes the risk profile:
- Patent litigation risk is relatively low.
- Manufacturing and regulatory-entry risk is relatively high.
- Product substitution risk is driven by clinical innovation rather than patent expiration.
- Takeda’s defensive position depends more on know-how and supply reliability than on exclusivity certificates.
What is the competitive landscape for FEIBA?
FEIBA competes in a specialized market with two distinct treatment segments: acute bypassing therapy and prophylaxis.
| Competitor |
Company |
Mechanism or role |
Competitive effect on FEIBA |
| Hemlibra |
Roche |
Bispecific non-factor prophylaxis |
Reduces spontaneous and breakthrough bleeding |
| NovoSeven RT |
Novo Nordisk |
Recombinant activated factor VII |
Direct bypassing-agent competitor |
| Alhemo |
Novo Nordisk |
Anti-tissue factor pathway inhibitor |
Adds prophylactic alternative for inhibitor patients |
| Porcine factor VIII |
Takeda and others |
Replacement therapy with reduced inhibitor cross-reactivity |
Substitutes in selected hemophilia A patients |
| Immune tolerance induction |
Multiple providers |
Reduces or eliminates inhibitors |
Reduces long-term bypassing-agent dependence |
| Conventional factor concentrates |
Multiple providers |
Factor replacement |
Relevant when inhibitor burden is low or eliminated |
NovoSeven is the closest established pharmacologic substitute in acute bleeding. It uses recombinant activated factor VII and does not depend on the same plasma-derived factor-complex supply chain.
Emicizumab has the greatest structural impact on FEIBA because it shifts treatment from episodic rescue to routine prophylaxis. Patients receiving emicizumab may still require a bypassing agent for breakthrough bleeding, but FEIBA use can decline because total bleeding frequency is lower.
What is the financial trajectory for FEIBA?
Takeda does not provide a consistently reported standalone FEIBA revenue line in its principal public financial disclosures. Product revenue is commonly grouped with other plasma-derived therapies, hematology products or broader business-unit categories. This prevents a precise public calculation of annual growth, gross margin or geographic contribution.
The financial trajectory has four defining characteristics:
Mature revenue base
FEIBA has a long commercial history and serves a narrow patient population. Its revenue is tied to the number of inhibitor patients, bleeding frequency, surgical utilization and treatment protocols rather than broad population expansion.
Pressure from prophylaxis
The largest demand risk is the movement of hemophilia care toward non-factor prophylaxis. Hemlibra has reduced reliance on bypassing agents in hemophilia A with inhibitors. Alhemo adds another prophylactic option, although adoption and market access will determine the magnitude of its effect.
Resilient episodic demand
FEIBA remains important for acute bleeding and surgery. Even patients receiving prophylaxis can require rescue therapy. This creates a residual demand base that is less exposed to complete product substitution than a purely chronic maintenance medicine.
Supply-chain value
Plasma-derived products can maintain pricing and customer retention when manufacturers demonstrate reliable supply. The product’s commercial value is supported by specialized production requirements and limited qualified capacity. These factors may protect revenue even as unit demand declines.
The likely financial profile is flat to declining volume, offset in part by price, mix and continued use in high-acuity settings. The product is unlikely to be a major growth driver for Takeda’s pharmaceutical portfolio.
What revenue exposure does Takeda have?
Takeda’s revenue exposure to FEIBA is strategically smaller than its exposure to major products such as Entyvio, Takhzyro and immunoglobulin therapies. FEIBA is part of Takeda’s plasma-derived and rare-disease portfolio, but Takeda’s public reporting does not isolate its contribution with sufficient consistency for a precise percentage of company revenue.
The company’s exposure is more relevant to the hematology franchise than to consolidated corporate results. A material decline in FEIBA would likely have a limited effect on Takeda’s total revenue but could affect the economics of its plasma-derived manufacturing network.
The product can still contribute attractive portfolio value because:
- The disease population is specialized.
- Treatment decisions are protocol-driven.
- Hospital and hemophilia-center relationships support retention.
- Manufacturing know-how limits immediate replacement.
- Acute bleeding products can command premium pricing relative to commodity factor products.
What generic or biosimilar entry risks exist?
A conventional generic launch is unlikely to follow the standard Hatch-Waxman Paragraph IV model. The principal entry risks are:
- A competing recombinant bypassing agent gaining clinical preference.
- Wider adoption of emicizumab or other prophylactic agents.
- A new biologic or plasma-derived competitor receiving regulatory approval.
- Hospital protocols shifting away from FEIBA in favor of NovoSeven.
- Manufacturing disruption or plasma shortages affecting supply reliability.
- New safety data increasing concern about thrombosis or thrombotic microangiopathy.
Biosimilar competition is also less straightforward than for monoclonal antibodies. Plasma-derived products have complex mixtures, variable source material and difficult analytical comparability requirements. A competitor would need to demonstrate consistent clinical performance and adequate pathogen-safety controls, not merely replicate a single defined protein sequence.
What patent litigation or settlement agreements affect FEIBA?
No major current U.S. patent litigation or Paragraph IV settlement involving FEIBA is identified in the standard public regulatory framework. The absence of a major patent dispute is consistent with the product’s age and its limited reliance on active Orange Book patents.
Commercial disputes are more likely to concern manufacturing, supply, procurement or reimbursement than patent validity. Litigation risk could increase if a competitor alleges infringement of process or manufacturing claims, but those claims are generally more difficult to assess from public product-level information.
How does FEIBA compare with NovoSeven and Hemlibra?
| Factor |
FEIBA |
NovoSeven |
Hemlibra |
| Manufacturer |
Takeda |
Novo Nordisk |
Roche |
| Product class |
Plasma-derived bypassing complex |
Recombinant factor VIIa |
Bispecific antibody |
| Main role |
Acute bleeding and surgery |
Acute bleeding and surgery |
Routine prophylaxis |
| Inhibitor population |
Hemophilia A or B with inhibitors |
Hemophilia A or B with inhibitors and other indications |
Primarily hemophilia A |
| Supply dependency |
Human plasma |
Recombinant manufacturing |
Biologic cell-culture manufacturing |
| Thrombotic concern |
Important label warning |
Important safety consideration |
Important when combined with bypassing agents |
| Patent position |
Mature, likely expired core patents |
Mature product with established patent history |
Newer, stronger active patent estate |
| Main market risk |
Prophylaxis substitution |
Competition from other bypassing and non-factor agents |
Safety, reimbursement and new prophylactic competition |
FEIBA has a stronger position in established emergency and surgical protocols than in long-term prophylaxis. Hemlibra has the stronger growth profile because it addresses recurring prevention rather than episodic treatment.
What is the outlook for the anti-inhibitor coagulant complex market?
The market outlook is stable to negative in unit terms but remains commercially durable. Demand should persist because prophylaxis does not eliminate all bleeding events and because surgical management requires experienced bypassing-agent options.
The principal market scenarios are:
| Scenario |
Market effect |
| Base case |
Gradual volume erosion with continued acute and surgical use |
| Downside case |
Faster decline as prophylaxis expands and hospital protocols change |
| Stable case |
Revenue maintained through price, severe-case utilization and supply reliability |
| Upside case |
Temporary demand increase from supply shortages affecting alternatives or increased surgical use |
Geographically, the United States remains commercially important because of high treatment intensity and access to specialty therapies. Western Europe and Japan have established hemophilia infrastructure but may impose greater pricing pressure. Emerging markets offer patient growth but face reimbursement, diagnosis and plasma-product access constraints.
Key Takeaways
- FEIBA is a mature plasma-derived bypassing agent for hemophilia patients with inhibitors.
- Takeda is the principal commercial sponsor.
- Public filings do not provide a reliable standalone FEIBA revenue series.
- The product has no apparent remaining composition-patent exclusivity that would create a future U.S. patent cliff.
- Paragraph IV litigation is not the main competitive threat.
- Manufacturing know-how, plasma sourcing and regulatory controls are more important barriers than patents.
- Hemlibra and Alhemo create the strongest long-term demand pressure.
- NovoSeven remains FEIBA’s closest direct pharmacologic competitor in acute bleeding.
- Revenue is likely to be stable to declining, with resilience from surgery, breakthrough bleeding and limited qualified supply.
- FEIBA remains strategically valuable but is unlikely to be a major growth product for Takeda.
FAQs about anti-inhibitor coagulant complex
Is anti-inhibitor coagulant complex the same as FEIBA?
Yes. FEIBA is the principal branded product associated with anti-inhibitor coagulant complex, also known as factor VIII inhibitor bypassing activity.
Can FEIBA be used with Hemlibra?
FEIBA can be used only under strict specialist oversight in patients receiving Hemlibra. The FDA label warns of thrombotic microangiopathy and thrombosis with the combination, particularly at high cumulative FEIBA doses.
Is FEIBA a biosimilar?
No. FEIBA is a complex plasma-derived coagulation product, not a biosimilar to a monoclonal antibody or a single recombinant protein.
Does FEIBA have a generic equivalent?
No conventional FDA generic equivalent is established. Any competitor would face biologic, manufacturing, plasma-safety and clinical comparability requirements.
What is the largest long-term threat to FEIBA revenue?
The largest threat is reduced use of bypassing agents as hemophilia centers adopt effective prophylactic therapies, particularly emicizumab and newer anti-tissue factor pathway inhibitors.
References
-
U.S. Food and Drug Administration. (2020). FEIBA [anti-inhibitor coagulant complex] prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
-
Takeda Pharmaceutical Company Limited. (2024). Annual report 2024. Takeda.
-
Roche. (2024). Hemlibra prescribing information. Genentech, a member of the Roche Group.
-
Novo Nordisk. (2024). Alhemo prescribing information. Novo Nordisk.
-
World Federation of Hemophilia. (2023). Guidelines for the management of hemophilia (3rd ed.). World Federation of Hemophilia.
